Takeda's Zasocitinib Achieves Phase 3 Success in Moderate to Severe Plaque Psoriasis
Key Insights
Takeda (search)'s oral drug zasocitinib achieved "clear or almost clear skin" in more than half of patients with moderate to severe plaque psoriasis (search) in Phase 3 trials.
Approximately 30% of patients achieved "completely clear skin" with the investigational treatment.
The drug met all efficacy goals across two randomized, controlled Phase 3 clinical trials.
Takeda (search) Pharmaceutical Company announced positive results from two Phase 3 clinical trials evaluating zasocitinib, an oral drug for moderate to severe plaque psoriasis (search). The investigational treatment demonstrated significant efficacy, with more than half of patients achieving "clear or almost clear skin" and approximately 30% reaching "completely clear skin."
Phase 3 Trial Results
The oral drug zasocitinib met all efficacy goals across two randomized, controlled Phase 3 clinical trials in patients with moderate to severe plaque psoriasis (search). The achievement of clear or almost clear skin in over 50% of patients represents a substantial clinical response rate for this patient population.
The complete skin clearance rate of approximately 30% further underscores the therapeutic potential of zasocitinib as a treatment option for psoriasis patients who currently face limited oral therapy choices.
Regulatory Timeline
Based on these positive Phase 3 results, Takeda (search) intends to submit zasocitinib for FDA approval in 2026. This regulatory submission timeline positions the drug as a potential new oral treatment option that could expand therapeutic choices for patients with moderate to severe plaque psoriasis (search).
The successful completion of Phase 3 trials marks a significant milestone in zasocitinib's development program, bringing the oral therapy closer to potential market availability for psoriasis patients seeking alternatives to current treatment regimens.